

# Koen Degeling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1190833/publications.pdf>

Version: 2024-02-01

21  
papers

262  
citations

1162889

8  
h-index

996849

15  
g-index

22  
all docs

22  
docs citations

22  
times ranked

488  
citing authors

#	ARTICLE	IF	CITATIONS
1	Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation. <i>European Radiology</i> , 2022, 32, 3067-3075.	2.3	11
2	Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance. <i>Cancers</i> , 2022, 14, 1783.	1.7	3
3	Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. <i>European Journal of Haematology</i> , 2022, 108, 469-485.	1.1	4
4	Evaluating the resource implications of different service delivery models for offering additional genomic findings. <i>Genetics in Medicine</i> , 2021, 23, 606-613.	1.1	5
5	Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening. <i>Value in Health</i> , 2021, 24, 206-215.	0.1	4
6	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. <i>Diagnostics</i> , 2021, 11, 103.	1.3	33
7	An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 359-367.	0.7	59
8	Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review. <i>European Urology Open Science</i> , 2021, 27, 77-87.	0.2	1
9	Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 953-964.	1.7	14
10	Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer. <i>Value in Health</i> , 2021, 24, 1737-1745.	0.1	4
11	Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. <i>Value in Health</i> , 2021, 25, 104-115.	0.1	2
12	Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 240.	1.0	4
13	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020, 38, 1263-1275.	1.7	3
14	Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process. <i>Medical Decision Making</i> , 2020, 40, 348-363.	1.2	8
15	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020, 38, 683-713.	1.7	10
16	A scoping review of metamodeling applications and opportunities for advanced health economic analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 181-187.	0.7	10
17	Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer. <i>Medical Decision Making</i> , 2019, 39, 57-73.	1.2	10
18	Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. <i>Cancer Epidemiology</i> , 2018, 57, 60-67.	0.8	18

#	ARTICLE	IF	CITATIONS
19	A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 17-25.	0.7	25
20	Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. <i>Value in Health</i> , 2017, 20, 1411-1419.	0.1	7
21	Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. <i>BMC Medical Research Methodology</i> , 2017, 17, 170.	1.4	19